◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 0241

Alibaba Health Information Technology Limited (0241) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Pharmaceutical Retailers · DATA UPDATED 2026-08-10

Alibaba Health Information Technology Limited (0241) operates in the Pharmaceutical Retailers industry and is headquartered in Causeway Bay, Hong Kong with about 1,394 employees. Its market capitalization is roughly CNY 59 billion. In the fiscal year ended 2026-03-31, 0241 reported CNY 34.3B in revenue and CNY 1.9B in net income.

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in the People's Republic of China.

Interactive charts & full statements →

0241 Revenue & Earnings History — Annual Income Statement

Income statement2026-03-312025-03-312024-03-312023-03-312022-03-31
Total RevenueCNY 34.3BCNY 30.6BCNY 27.0BCNY 26.8B
Gross ProfitCNY 8.2BCNY 7.4BCNY 5.9BCNY 5.7B
Operating Income (EBIT)CNY 1.9BCNY 1.6BCNY 712MCNY 51M
Net IncomeCNY 1.9BCNY 1.4BCNY 884MCNY 536M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

0241 Free Cash Flow History

0241 Balance Sheet History

Balance sheet2026-03-312025-03-312024-03-312023-03-312022-03-31
Total AssetsCNY 23.1BCNY 21.2BCNY 19.7BCNY 20.7B
Total LiabilitiesCNY 5.2BCNY 4.9BCNY 5.2BCNY 5.6B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 0241 viewer.

Other Companies in Pharmaceutical Retailers

← 0240All “0-9” companies0242 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.